Format

Send to

Choose Destination
Cancer. 2017 Jun 1;123(S11):2130-2142. doi: 10.1002/cncr.30681.

Interaction of molecular alterations with immune response in melanoma.

Author information

1
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
2
Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
3
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Abstract

Major advances have been made in melanoma treatment with the use of molecularly targeted therapies and immunotherapies, and numerous regimens are now approved by the US Food and Drug Administration for patients with stage IV disease. However, therapeutic resistance remains an issue to both classes of agents, and reliable biomarkers of therapeutic response and resistance are lacking. Mechanistic insights are being gained through preclinical studies and translational research, offering potential strategies to enhance responses and survival in treated patients. A comprehensive understanding of the immune effects of common mutations at play in melanoma is critical, as is an appreciation of the molecular mechanisms contributing to therapeutic resistance to immunotherapy. These mechanisms and the interplay between them are discussed herein. Cancer 2017;123:2130-42.

KEYWORDS:

B-Raf proto-oncogene serine/threonine kinase (BRAF); catenin-β 1 (CTNNB1); combination therapy; guanosine-triphosphate guanyltransferase (GTPase); immunotherapy; melanoma; neoantigen; neuroblastoma rat sarcoma viral oncogene homolog (NRAS); personalized medicine; phosphatase and tensin homolog (PTEN); targeted therapy

PMID:
28543700
PMCID:
PMC6105277
DOI:
10.1002/cncr.30681
[Indexed for MEDLINE]
Free PMC Article

Publication type, MeSH terms, Substances, Grant support

Publication type

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center